Bordeaux Wealth Advisors LLC Sells 728 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Bordeaux Wealth Advisors LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 32.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,537 shares of the medical research company's stock after selling 728 shares during the quarter. Bordeaux Wealth Advisors LLC's holdings in Thermo Fisher Scientific were worth $765,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of TMO. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $25,000. Pillar Financial Advisors LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $29,000. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $30,000. Noble Wealth Management PBC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $35,000. Finally, Cassady Schiller Wealth Management LLC boosted its position in Thermo Fisher Scientific by 89.2% during the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after acquiring an additional 33 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on TMO. Evercore ISI decreased their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Barclays dropped their target price on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a research report on Tuesday, June 24th. Royal Bank Of Canada reduced their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Scotiabank cut their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research report on Friday, April 25th. Finally, Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $604.05.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Down 1.1%

Shares of NYSE:TMO traded down $4.45 during trading on Friday, reaching $407.67. The stock had a trading volume of 3,922,604 shares, compared to its average volume of 2,584,448. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The firm's fifty day moving average is $409.74 and its 200 day moving average is $483.23. The stock has a market cap of $153.89 billion, a price-to-earnings ratio of 18.64, a P/E/G ratio of 2.17 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm's revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the business earned $5.11 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.